Apo-Terazosin

国: ニュージーランド

言語: 英語

ソース: Medsafe (Medicines Safety Authority)

有効成分:

Terazosin hydrochloride dihydrate 5.95mg equivalent to terazosin 5 mg

から入手可能:

Apotex NZ Ltd

INN（国際名）:

Terazosin hydrochloride dihydrate 5.95 mg (equivalent to terazosin 5 mg)

投薬量:

5 mg

医薬品形態:

Tablet

構図:

Active: Terazosin hydrochloride dihydrate 5.95mg equivalent to terazosin 5 mg Excipient: Ferrosoferric oxide Iron oxide red Lactose Magnesium stearate Microcrystalline cellulose Starch

パッケージ内のユニット:

Bottle, plastic, white HDPE, PE cap,100 tablets, 100 tablets

クラス:

Prescription

処方タイプ:

Prescription

製:

Signa SA de CV

製品概要:

Package - Contents - Shelf Life: Bottle, plastic, white HDPE, PE cap,100 tablets - 100 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, white HDPE, PE cap,500 tablets - 500 tablets - 36 months from date of manufacture stored at or below 25°C

承認日:

2003-04-23

製品の特徴

NEW ZEALAND DATA SHEET
APO-TERAZOSIN
Please refer to Medsafe website (www.medsafe.govt.nz) for the most
recent datasheet Page 1
1.
PRODUCT NAME
APO-TERAZOSIN (1mg, 2mg and 5mg tablets)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Terazosin 1mg, 2mg & 5mg (as hydrochloride dihydrate)
EXCIPIENT(S) OF KNOWN EFFECT
Apo-Terazosin does not contain gluten.
Apo-Terazosin contains lactose.
If you have been told by your doctor that you have intolerance to some
sugars contact your doctor before
taking this medicinal product.
This should be taken into account in patients with diabetes mellitus.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
APO-TERAZOSIN 1mg tablets are white, round, flat-faced, beveled-edge
tablet, engraved “APO” on one
side and “T1” on the other side. Each tablet typically weighs
approximately 150mg.
APO-TERAZOSIN 2mg tablets are orange, round, flat-faced, beveled edged
tablet, engraved “APO” on one
and “T2” on the other side. Each tablet weighs approximately
150mg.
APO-TERAZOSIN 5mg tablets are tan, round, flat-faced, beveled edged
tablet, engraved “APO” on one
and “T5” on the other side. Each tablet weighs approximately
150mg.
Please note: These tablets are not capable of providing a divided
dose. Do not halve the tablets.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Terazosin is indicated for the symptomatic and pathophysiologic
treatment of benign prostatic hyperplasia
(BPH) when:
prostatectomy is not indicated
patient is not fit for surgery
elective surgery must be postponed (e.g., waiting list)
patient refuses surgical treatment.
(See section 4.5Interactions with other medicines and other forms of
interactions)
Terazosin is also indicated in the treatment of hypertension. It can
be used alone or in combination with
other antihypertensive agents such as diuretics or beta-adrenergic
blocking agents.
4.2 DOSE AND METHOD OF ADMINISTRATION
DOSE
The dose of Terazosin should be adjusted according to the patient’s
responses. The following is a guide to